Allogeneic hematopoietic stem cell transplantation (Allo-HSCT), proposed to patients with
high-risk myeloid malignancies, may ultimately fail because of disease relapse. Bone …

Background: Disease relapse remains the main cause of mortality after allogeneic stem cell
transplantation (allo-SCT) for patients with myeloid malignancies. Loss of donor chimerism …

In patients who have undergone allogeneic hematopoietic cell transplantation (HCT),
myeloid mixed donor chimerism (MC) is a risk factor for disease relapse. In contrast, several …

We used multiplex amplification of nine microsatellite sequences (PCR-STR) to analyse
chimerism in pure populations of T cells and neutrophils from peripheral blood from 40 …

Incomplete donor chimerism (DC) after hematopoietic stem cell transplantation (HSCT) is
associated with reduced overall and disease-free survival and decreasing DC can precede …

Allogenic stem cell transplantation (HCT) is a potentially curative treatment for patients with
various hematologic malignancies. Following HCT it is common practice to assess …

After allogeneic hematopoietic stem‐cell transplantation (alloHSCT), the chimerism assay is
used to monitor cell engraftment and quantify the respective proportions of donor/recipient …

Background. Although CD34+ progenitors play a crucial role during bone marrow
transplantation (BMT), there is only scant knowledge concerning their lineage-restricted …

Background The importance of chimerism status in the very early period after hematopoietic
stem cell transplantation is unclear. We determined PBMC and T-cell donor chimerism 50 …

Introduction Chimerism analysis after allogeneic hematopoietic stem cells transplantation
(HSCT) allows documentation and understanding of important clinical events such as …